Bayer sells oncology asset Stivarga for €375m
German global life science and pharmaceutical company Bayer has divested its established oncology asset Stivarga to the German pharmaceutical firm Grünenthal for a total consideration of up to €375m. The transaction, announced in September 2026, involves the transfer of rights for Stivarga, also known as regorafenib, which is a once daily oral multikinase inhibitor approved in more than 90 markets…
Merck signs $2.1bn SciBrunch Oncology Deal
Multinational biopharmaceutical company Merck has entered into an exclusive global licensing agreement with Chinese biotechnology firm SciBrunch Therapeutics for the development and commercialisation of SPR2015. SPR2015 is an investigational, preclinical, oral molecular glue inhibitor specifically engineered to target a mutation which is one of the most prevalent genetic alterations across major malignancies, including pancreatic, colorectal, and non small cell lung…
Archimed taking Esperion private in $1.1bn deal
Pharmaceutical company Esperion Therapeutics has announced it has entered into a definitive agreement to be acquired by the healthcare focused investment firm Archimed in a $1.10bn deal. Esperion, a commercial-stage biopharma group dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, has faced competitive pressures in the lipid lowering market and looking forward, will need to contend with…
Chiesi to buy KalVista in $1.9bn deal
Italian biopharmaceutical firm Chiesi Group has struck a definitive agreement to acquire listed KalVista Pharmaceuticals in an all-cash transaction valued at approximately $1.9bn. The transaction has secured unanimous approval from both corporate boards and is slated to close in the third quarter of 2026, subject to customary regulatory clearances and the tender of a majority of shares. Under the terms…
Gilead Expands oncology portfolio with $5bn Tubulis deal
Listed American biopharmaceutical company Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a privately held German biotechnology company, for a total potential consideration of $5bn. Under the terms of the deal, Gilead will provide an upfront cash payment of $3.15bn, with an additional $1.85bn tied to future contingent milestones. The transaction is expected to close in the…
Hygie31 acquires Spanish pharmacy group CentralFarma
French healthcare group Hygie31 has continued its rapid expansion strategy with the acquisition of prominent Spanish pharmacy group CentralFarma. The new structure will bring together more than 400 pharmacies and is expected to generate a turnover of over €600 million by the end of 2026. The move reinforces the group’s position as a leading consolidator in the pharmacy and health…
Novartis expands clinical pipeline with multi-billion dollar acquisitions
Novartis has expanded its clinical pipeline through the back to back acquisitions of Pikavation Therapeutics and Excellergy. The Swiss pharmaceutical giant is seeking to offset looming patent expiries for major brands such as Entresto and Promacta. The first transaction involves the acquisition of Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics, for $3bn. Under the definitive agreement, Novartis will pay $2bn…
Merck’s acquiring Terns Pharmaceuticals in $6.7bn transaction
Multinational pharma group Merck has reached a definitive agreement to acquire pharmaceutical research company Terns Pharmaceuticals in a transaction valued at approximately $6.7bn. This move is widely viewed as a strategic manoeuvre to bolster Merck’s oncology and haematology pipeline as the company prepares for the anticipated loss of exclusivity for its blockbuster cancer therapy, Keytruda, later this decade. The primary…
GSK buying biopharmaceutical group 35Pharma for $950m
British multinational biopharmaceutical company GSK has reached a definitive agreement to acquire 35Pharma, a Canada-based clinical-stage biopharmaceutical company, for a total cash consideration of $950 million. The deal centres on 35Pharma’s lead asset, HS235, which is a potential best-in-class protein-based therapeutic designed to treat cardiopulmonary diseases. This investigational medicine has successfully completed phase I trials in healthy volunteers and is prepared…
Reset Health and Pharmacy2U partner on weight loss
The UK’s largest dedicated online pharmacy Pharmacy2U and UK-based digital health company Reset Health have announced a strategic partnership, marking a significant shift in the UK obesity market by combining digital pharmacy scale with specialised clinical oversight. The collaboration, set to launch Q1 2026, pairs the UK’s largest online pharmacy with Reset Health’s experience in managing chronic diseases through a…